Amylyx Pharma dips after stock offering launch

Amylyx Pharmaceuticals

09/09/2025 21:56

** Shares of Amylyx Pharmaceuticals AMLX.O down 2.3% in
    extended trading to $10.27 as it seeks equity raise

    ** Cambridge, Massachusetts-based Amylyx announces stock offering without disclosing deal size

** Co intends to use net offering proceeds to fund commercial readiness for Avexitide, its drug for post-bariatric hypoglycemia, a condition in which people who have had weight-loss surgery experience dangerously low blood sugar levels

** Leerink and Guggenheim are lead bookrunners for the offering

** Last month, the U.S. FDA withdrew approval for AMLX's ALS drug, and co said it would stop development of its rare brain disorder drug after trial failure

** Co has ~89.2 mln shares outstanding for roughly $930 mln market cap

** AMLX shares on Tues finished up 0.7% at $10.51, up 178% YTD

** 9 of 10 analysts covering rate stock "strong buy" or "buy" and 1 has "hold"; median PT is $12, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))